Since it was developed in 2016, we’ve blogged several times about esketamine—the isomer of ketamine being developed by Janssen Pharmaceuticals, designed to rapidly alleviate the symptoms of treatment-resistant depression. Esketamine, which will be administered...
For many women, giving birth is the most joyous event of their lives. But, every year, for more than 3 million women in the U.S., child birth results in the development of postpartum depression—and it can be devastating for mother and child alike. Most cases of...
There is no one-size-fits-all solution for depression. Even though 17% of people will suffer from depression over the course of their lives, modern medicine is still searching for a comprehensive solution. Traditional antidepressant medications are the first line of...
More than 300 million people in the world suffer from clinical depression, but 50% of them will never seek treatment. Rather, these people suffer from such symptoms as sadness, inability to concentrate, and loss of appetite—with limited hope for improvement. Many...
In April 2018, we shared some promising information about a Yale School of Medicine study that found ketamine to be highly effective in reducing the symptoms of depression in a 16-year old patient suffering from suicidal ideations. After having declared himself...
